Nexstim Plc announced that the Data Safety Monitoring Board (DSMB), an independent committee of experts monitoring the Phase III stroke therapy NICHE trial, has reviewed the interim analysis data. The DSMB notes that the pre-specified stopping criteria for futility have been met and therefore the trial will not meet its primary endpoint. However, the DSMB further notes that they acknowledge that the treatments and enrolment have been completed. They recommend that the study team and subjects remain blinded and data collection be completed.

Cardiac stem cells could be an effective treatment for a common but difficult-to-treat type of heart failure, a new study from the Cedars-Sinai Heart Institute shows.

JC Medical Inc. announced that it has successfully completed an implantation of its J-Valve bioprosthesis using the Ausper transapical delivery device in Vancouver, Canada. The J-Valve Ausper system represents the next generation of transcatheter aortic valve implantation (TAVI) systems and has been previously used in more than 100 patients in China. This operation is the first implantation of the J-Valve Ausper system outside of China.

February 29, 2016 — Abbott has initiated a voluntary safety notice regarding the MitraClip Delivery System to reinforce ...

Investing in Toshiba Medical, which is seeking potential partners, is likely to deliver strong returns for companies looking to expand into the diagnostic imaging space, according to an analyst with research and consulting firm GlobalData. This could be particularly attractive in the Japanese market, according to the analyst.

A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in significant improvement of functional mitral regurgitation (FMR), a condition that can increase the symptoms of heart failure. The study was recently published in the Journal of Invasive Cardiology.